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Although the real prevalence of ischemic nephropathy as a
cause of end-stage renal disease is unknown, its incidence has
increased in past years. The diagnosis of this pathology requires
that a number of functional and anatomic tests be carried out.
The initial approach should be to perform duplex Doppler ul-
trasonography which, besides providing data on the size and
extent of the stenosis, enables the intrarenal resistive index to
be estimated to determine the pattern of renal parenchyma in-
jury and the expected progression if revascularized.
The most frequently used morphologic techniques are mag-
netic resonance angiography and computer tomography an-
giography. In the event of ischemic neuropathy, it is necessary
to perform a renal arteriography regardless of the inherent risks
of contrast toxicity or atheroembolism.
Various therapeutic options are reviewed, with emphasis on
percutaneous transluminal renal angiography plus stent as the
first indication. Even though initial reports were contradictory,
several meta-analyses have concluded that better blood pres-
sure control and renal function improvement are achieved with
percutaneous transluminal renal angiography plus stent than
with conventional medical therapy. Surgical revascularization
is preferable in patients with severe aorto-iliac pathology and
renal artery ostium complete thrombosis. The risks and benefits
of these procedures must be evaluated on an individual basis.
Ischemic nephropathy (IN) can be defined as a sig-
nificant reduction in glomerular filtration rate (GFR) in
patients with hemodynamically significant renovascular
occlusive disease (RVD) affecting the entire functional
renal parenchyma. This clinical entity has been described
by various authors as ischemic renal disease, chronic renal
ischemic disease, azotemic RVD, atherosclerotic RVD, or
renal insufficiency of renovascular hypertension [1].
The prevalence of IN has not been precisely estab-
lished, but various autopsy-related studies have reported
a prevalence of 18% among patients aged 64 to 75 years
and 42% among patients older than 75 years. Thus, the
prevalence of IN seems to depend on the age of the pop-
ulation, increasing at greater ages. Disease prevalence
among those presenting for angiography ranged from
Key words: ischemic nephropathy, ischemic renal disease, renovascular
disease, atherosclerotic renal artery disease, percutaneous transluminal
renal angioplasty.
C© 2005 by the International Society of Nephrology
11% to 42%, with the greatest prevalence in those with
generalized atherosclerosis, peripheral vascular disease,
and aortic atherosclerotic disease [2, 3]. Chronic renal
failure due to ischemic RVD is a potentially reversible
disorder. Progressive renal artery stenosis that threat-
ens the entire renal mass, potentially resulting in renal
insufficiency or end-stage renal disease (ESRD), is usu-
ally defined as significant high-grade stenosis of both re-
nal arteries or as stenosis of a single kidney. It has been
estimated that it may be responsible for 5% to 22% of
cases of advanced renal failure in patients who are older
than 50 years [4]. In one study, IN was diagnosed as the
primary cause of ESRD in patients older than 65 years.
In another series of bilateral RVD, 12% of cases pro-
gressed to ESRD and had an average decline in GFR of
8 mL/min/year [5].
Fatica et al reported that the incidence of ESRD caused
by IN was increasing at an annual rate of 12.4% for
RVD-ESRD over the study period, which was greater
than that of diabetes mellitus-ESRD (8.4%) or all-cause
ESRD (5.4%) [6]. Clinical findings associated with the
presence of RVD are hypertension, advanced age, renal
insufficiency, extrarenal atherosclerosis, renal artery or
abdominal bruit, diabetes mellitus, congestive heart fail-
ure symptoms, female sex, and smoking.
A multicenter study conducted by the Spanish Group
of Ischemic Nephrology (GEDENI) [7], which involved
20 Spanish hospitals, reported a mean age of 68.7 years
and a predominance of men (78.3%) among 156 IN pa-
tients. Most of them were hypertensive (97.4%), smok-
ing (69.8%), and hypercholesterolemic (62.9%). Isolated
or associated atherosclerosis in other vascular beds was
present in 82% of patients, peripheral arteriopathy was
observed in more than 65% of patients, and associated
arteriopathy or ischemic cardiomyopathy was observed
in 21.6% of patients.
Renal insufficiency and hypertension are the predom-
inant clinical features of IN. However, according to a
report published by Alcazar et al, 29.5% of patients deve-
loped acute renal failure (ARF) as the IN presentation;
in 12 patients (57%), it was secondary to angiotensin-
converting enzyme inhibitor (ACE-I) treatment, and in
28.5% of patients, it was due to renal artery occlusion
[8]. The kidney can develop collateral circulation at the
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expense of the lumbar, urethral, and suprarenal arteries.
Therefore, the kidney may survive despite a very low fil-
tration pressure and GFR.
In another series [9, 10], it was reported that 6% to
38% of patients with severe RVD develop ARF when
treated with ACE-I. Similarly, angiotensin II receptor an-
tagonists (AIIRA) may produce the same hemodynamic
disorder as ACE-I and thus precipitate ARF [9, 10].
DIAGNOSTIC APPROACH
Because there are several clinical signs that suggest
a diagnosis of IN, it is important to perform a com-
plete anamnesis and physical examination. Signs and
symptoms that indicate IN are: sudden onset of hyper-
tension, especially in young patients and particularly in
women; the presence of severe hypertension with signs of
atherosclerosis in other vascular territories in men older
than 60 years; hypertension and vascular bruit; grade III
retinopathy in 25% to 40% of patients; elevation of serum
creatinine levels after administration of ACE-I or AI-
IRA; episodes of cardiac failure and acute pulmonary
edema; and hypertension refractory to treatment with
drugs other than antihypertensive drugs.
However, the diagnosis should rely on imaging studies
to enhance the specificity of clinical findings. Ideally, the
screening test should be readily available, noninvasive,
non-nephrotoxic, and should provide an anatomic diag-
nosis of IN as well as an indication of its functional sig-
nificance. In addition, it should also provide information
on which patients are likely to benefit from intervention
[11].
The gold standard for diagnosing renal artery steno-
sis is renal arteriography. However, several less-invasive
tests have been evaluated for screening purposes. False-
negative tests (low sensitivity) are the major concern with
all noninvasive tests, because patients with a potentially
correctable cause of hypertension may be overlooked.
Duplex doppler ultrasonography
In centers that have used duplex Doppler ultrasonog-
raphy for some time, the sensitivity and specificity of this
test were reported to be greater than 96% when both in-
trarenal and extrarenal arterial analyses were combined.
Its most significant limitation relates to localization of
the renal arteries. The limitation depends on the degree
of abdominal obesity, intestinal gas content, experience
and patience of the observer, and time spent performing
the examination; thus, it has been criticized as observer
dependent.
Duplex Doppler ultrasound enables calculation of a re-
sistive index, of a measure of the integrity of small vessel
circulation, and of parenchymal injury. A resistive index
value greater than 0.80 for the kidney contralateral to
a stenosis indicates severe parenchymal disease, a small
likelihood of clinical benefit from blood pressure control,
and renal function recovery from revascularization. The
resistive index is decreased in stenotic kidneys because
of waveform dampening, and therefore lower values may
not reflect preserved parenchyma. However, a resistive
index greater than 0.80 in a stenotic kidney indicates that
severe parenchymal disease is likely and that there will
be a poor clinical response to revascularization. For these
reasons, duplex Doppler ultrasound is an appropriate ini-
tial screening test when expertise is available [12].
Renal scintigraphy
Currently, this technique is used only to demonstrate
renal feasibility in patients with nonfunctioning kidneys.
Magnetic resonance angiography
Magnetic resonance angiography (MRA) is a noninva-
sive test that involves the administration of gadolinium,
a non-nephrotoxic contrast agent. In centers where reli-
able duplex Doppler testing is unavailable, gadolinium-
enhanced MRA is likely to be the screening test of
choice. The main problems with MRA are its tendency
to overestimate the severity of the stenosis and its degree
of interobserver variability. The use of gadolinium-
enhanced three-dimensional MRA improves the speci-
ficity of the examination. For diagnosis of atherosclerotic
renal artery stenosis >50%, the sensitivity and specificity
of gadolinium-enhanced MRA are 97% and 93%, re-
spectively, and 94% and 85% for non-enhanced MRA.
Combination of the MRA with cardiac-gated phase con-
trast flow measurements can facilitate assessment of the
hemodynamic significance of a stenosis. Use of the com-
bined protocol may permit a more accurate assessment of
the degree of stenosis and reduce interobserver variabil-
ity. Recently, combined MRA and phase contrast mag-
netic resonance have shown promise for estimating the
functional significance of a stenosis from the renal artery
differential pressure across the stenosis [13]. These new
techniques are currently under study and are therefore
not routinely used in many centers. To date, MRA pro-
cedures have not proven useful in predicting clinical re-
sponses to revascularization.
Spiral computed tomographic angiography
The sensitivity of this method varies from 67% to 92%
[27]. It can be improved to 98%, with a specificity of
84%, by using maximum-intensity projections and three-
dimensional techniques. The need to administer 100 to
150 mL of iodine contrast material is one of the disad-
vantages of this method, making it undesirable for pa-
tients with renal insufficiency. Furthermore, as is the case
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with MRA, computed tomographic angiography (CTA)
provides only anatomic information and has not been
shown to predict clinical responses to revascularization
[14].
The ability of CTA, MRA, ultrasonography, captopril
scintigraphy, and the captopril test to detect IN were
recently compared in a meta-analysis of 55 studies of
patients referred for the evaluation of renovascular hy-
pertension [15]. CTA and gadolinium-enhanced MRA
had the highest diagnostic performance. However, both
CTA and gadolinium-enhanced MRA (without phase
contrast flow measurements or estimations of pressure
gradients) provide only an anatomic diagnosis of ather-
osclerotic renal artery stenosis.
The diagnostic use of angiographic methods car-
ries a risk of radiocontrast-induced nephrotoxicity and
atheroembolism. The best treatment for contrast-induced
renal failure is prevention. Preventive measures include
the use, if clinically possible, of scanning without radio-
contrast agents, particularly in high-risk patients; the use
of lower doses of contrast and avoidance of repetitive
studies that are closely spaced; avoidance of volume de-
pletion or nonsteroidal anti-inflammatory drugs, both of
which can increase renal vasoconstriction; the adminis-
tration of intravenous saline solution and the antioxidant
acetylcysteine; and the use of low or iso-osmolal non-
ionic contrast agents [16]. The primary benefit of non-
ionic contrast agents, whether low or iso-osmolal, is seen
in high-risk patients such as those with plasma creati-
nine concentrations greater than 1.5 to 2 mg/dL (132–
176 mmol/L), particularly if they are diabetic. In addi-
tion, contrast nephropathy among diabetics with renal
insufficiency may be much less likely with an iso-osmolal
nonionic contrast agent than with low osmolal nonionic
agents. The only currently available iso-osmolal non-
ionic agent, iodixanol, is expensive. Because low-osmolal
agents have replaced high-osmolal agents for almost all
intravascular radiologic procedures, the choice for clini-
cians in high-risk patients is largely between low osmolal
and iso-osmolal contrast media [17].
The safety and lack of nephrotoxicity of gadolinium-
based contrast agents in magnetic resonance (MR) imag-
ing studies for patients with normal or decreased renal
function are well established. As a result, among those
at risk for radiocontrast-induced nephropathy for whom
vascular imaging is required, MR imaging with gadolin-
ium is preferred to computed tomography or conven-
tional arteriography with iodinated contrast media. To
minimize possible nephrotoxicity in MR examinations,
doses of gadolinium-based contrast agents of more than
0.3 mmol/kg body weight should be avoided. The cur-
rent practice of using gadolinium-based contrast media
for digital subtraction angiography is limited by possible
nephrotoxicity and, if the dose is below 0.3 mmol/kg for
renal protection, diminished diagnostic image quality.
Among patients with chronic renal failure, the ad-
ministration of acetylcysteine in combination with saline
hydration and a nonionic, low-osmolal contrast agent
protected against contrast nephropathy in some studies
[18]. The benefit of acetylcysteine appears to be less con-
sistent in lower-risk patients with a lesser degree of renal
insufficiency. Because of these discrepancies, the over-
all prophylactic efficacy of acetylcysteine was assessed in
multiple meta-analyses. In a 2004 study, primary analy-
sis was performed among eight randomized controlled
trials that enrolled 885 patients. Compared with hydra-
tion alone, acetylcysteine plus hydration significantly re-
duced the risk of developing nephropathy after contrast
administration among those with chronic renal insuffi-
ciency (RR, 0.41; 95% CI, 0.22–0.79). However, this over-
all effect must be viewed in the context of the marked
variability in individual risk.
The DA-1receptors are particularly prominent in the
renal vasculature, renal tubules, mesenteric vasculature,
and peripheral vessels. The DA-1 receptor stimulation
vasodilates renal and peripheral vessels, causing a de-
crease in blood pressure and an increase in renal blood
flow. Animal testing with fenoldopam has indicated that
it is six times more potent than dopamine in its ability
to decrease renal vascular resistance; this suggests that it
could be a much more selective and potent renal protec-
tive agent against any toxin or stimulus that causes renal
dysfunction by reducing renal blood flowor increasing re-
nal ischemia. Fenoldopam has been used for patients who
were thought to be at the highest risk for contrast-induced
nephropathy, and results suggest that fenoldopam may
be of distinct benefit to high-risk patients who need in-
travascular contrast, especially those who may have to
receive a large contrast dose, such as patients undergoing
renal angiography [19]. Because available data are anec-
dotal, it is desirable that prospective, randomized trials
are conducted to compare the effects of fenoldopam with
those of hydration. The many advantages of carbon diox-
ide angiography for investigation of renal arterial disease
include absences of nephrotoxicity and allergic reaction
[20].
DIFFERENTIAL DIAGNOSIS
IN and nephroangiosclerosis usually become apparent
in men older than 50 years of age who have a history of
arterial hypertension and associated metabolic disorders.
The decline of renal function in nephroangiosclerosis is
slower than IN and is frequently accompanied by mild
proteinuria. Patients with systemic atherosclerosis have
a high risk of developing atheroembolism with small-
vessel thrombosis. Cholesterol atheroembolism is fre-
quently precipitated by aortic manipulation, although it
can arise spontaneously. The deterioration of renal func-
tion and existence of extrarenal lesions are manifested by
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digital gangrene, livedo reticularis, and the presence of
hypocomplementemia and blood and urine eosinophilia
[21].
Evidence of cholesterol embolization was found in
25% to 30% of patients who died within six months
of cardiac catheterization or aortography. In several re-
ports of renal artery angioplasty, cholesterol emboli were
present in 0.6% to 6% of patients, an overall incidence of
16 of 1014 attempted dilations. A comprehensive review
of noncoronary angioplasty (4662 renal and peripheral
cases) reported that the incidence of embolism was 4.8%.
TREATMENT
The aim of treatment is to protect or improve renal
function. Specific management in patients with chronic
ischemic renovascular diseases such as IN are medical
therapy, angioplasty (usually with stent placement), and
surgery. Candidates at risk for IN frequently need med-
ical therapy for other manifestations of atherosclerotic
disease. Many of the procedures used to reduce mortality
related to stroke and coronary disease affect atheroscle-
rotic kidneys [22]. Medical therapy with antihyperten-
sive drugs, particularly ACE-I or AIIRA, can effectively
control blood pressure in most patients with bilateral
renal artery stenosis. Hypertension can be resistant to
antihypertensive therapy; such patients may be candi-
dates for revascularization. Despite adequate control of
blood pressure, the chronic administration of an ACE-
I (and perhaps other antihypertensive drugs) may also
lead to atrophy behind the stenosis and will not prevent
progression of the stenotic lesions. In addition to issues
related to blood pressure control and progressive renal
artery atherosclerosis, these patients are also at risk for
extrarenal cardiovascular events. When evaluating ther-
apeutic efficacy, one must remember that the survival
rate of elderly, atherosclerotic, and hypertensive patients
undergoing dialysis is very low. Revascularization might
improve survival by slowing the progression of renal in-
sufficiency or enabling better control of hypertension.
Percutaneous transluminal renal angioplasty (PTRA)
with stent is an attractive option, because it is associ-
ated with relatively low morbidity and mortality [23].
However, its efficacy is reduced in patients with severe
atherosclerosis, especially when the ostium of the re-
nal artery is affected. Because most atheromatous renal
artery stenoses are ostial, the response to balloon dilata-
tion may be poor and must be taken into account when
PTRA is indicated. PTRA of ostial stenosis is successful
in only 50% of cases; the incidence of restenosis ranges
from 5% to 38%, and a large proportion of patients ex-
perience decreased renal function.
Although consensus has not been reached among in-
vestigators, revascularization is indicated in patients with
the following characteristics: a decrease in renal artery
diameter greater than 75%; progressive deterioration
of renal function in individuals with renovascular dis-
ease but with satisfactory control of arterial pressure;
nonreversible renal insufficiency in the presence of hy-
potensive drugs (excluding ACE-Is) as a consequence of
critical stenosis; a resistive index for duplex Doppler ul-
trasonography of less than 80; and renal failure caused by
aortic, unilateral, or bilateral renal artery thrombosis in
which the kidneys remained viable because of collateral
circulation. Van Jaasrveld et al [24] randomly assigned
106 patients with hypertension who had atherosclerotic
renal-artery stenosis and renal insufficiency to PTRA or
drug therapy To be included in the study, patients also had
to have a diastolic blood pressure of 95 mm Hg or higher
despite treatment with two antihypertensive drugs, or an
increase of serum creatinine concentration during treat-
ment with an ACE-I of at least 0.2 mg/dL (20 lmol/L).
Blood pressure, doses of antihypertensive drugs, and re-
nal function were assessed at months 3 and 12 of the study,
and patency of the renal artery was assessed at month 12.
They concluded that, for patients who have IN secondary
to atherosclerotic renal artery stenosis with normal or
mild impairment of renal function, primary angioplasty
was equally or less effective than antihypertensive drugs
alone for reducing blood pressure. Nevertheless, “rescue”
angioplasty to control refractory hypertension was effica-
cious. ACE-I renograms have little utility for the manage-
ment of IN, because they do not predict which patients
will respond to therapy.
Self-expanding and balloon-expandable metallic stents
[PTRA with stent (PTRAS)], which might improve an-
gioplasty results, immediate post-angioplasty complica-
tions, and restenosis, have recently became available for
atherosclerotic renal arterial stenosis. The most extensive
review to date on the efficacy of PTRA and PTRAS was
conducted by Leertouwer et al in 2000 [25]. They included
all studies dealing with PTRA (10 articles, 644 patients)
and PTRAS (14 articles, 678 patients). The population
selected shared similar characteristics: mild-to-moderate
renal insufficiency and aged 60 to 75 years. Primary out-
come measures were similar (change in renal function or
hypertension control, angiographic patency). They con-
cluded that PTRAS is superior to PTRA because of a
higher initial success rate and a lower restenosis rate.
Stent placement was associated with a significantly lower
percentage of patients with improved renal function.
However, it is likely that this is because the baseline renal
function was better in PTRAS studies. This meta-analysis
suggests that 65% to 70% of patients have stable or im-
proved renal function after PTRA/S.
Because of a lack of clear evidence for drawing up
definitive guidelines for IN, clinical practice is frequently
based on subjective criteria. Further studies in which re-
nal function is documented as the primary outcome are
needed. Multicenter, randomized studies are in progress
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to determine whether PTRAS improves the cardiovascu-
lar morbidity and mortality of patients.
The ASTRAL study will eventually include about 1000
IN patients [26]. Patients with a clinical presentation iden-
tified as IN are randomly assigned to PTRA with or with-
out stent placement plus medical care, or to medical care
alone. There are no restrictions on medical treatment of
patients, but ACE-I/AIIRA will only be used if consid-
ered essential, such as in cases of congestive heart failure.
The primary outcome is the mean slope of the reciprocal
plots of creatinine concentration over time.
The CORAL trial was designed to test the difference
in survival free of adverse cardiovascular and renal end
points in hypertensive patients [27]. It began in 2004
with a population of about 1000 IN cases and will con-
tinue for 5 years. The randomized design compares renal
artery stenting plus optimal medical therapy with opti-
mal medical therapy alone. ACE-I cases are not excluded
from therapy considered to be standard for the care and
management of patients with atherosclerotic disease. The
primary end point is a combination of cardiovascular or
renal death, stroke, myocardial infarction, hospitalization
for congestive heart failure, doubling of serum creatinine,
and renal replacement therapy.
Surgery is still the first treatment choice for patients
with IN of atherosclerotic origin. The main indications are
an aorto-iliac atherosclerotic condition requiring revas-
cularization, severe ostial stenosis, and complete renal
artery thrombosis. Traditionally, several criteria have
been used for the indication of revascularizing surgery:
total kidney size greater than 8 cm; angiographic or scinti-
graphic demonstration of retrograde filling of the distal
renal arterial tree from collateral vessels; patency of the
distal end of the renal artery; viability of the involved
kidney as shown by isotopic renography; well-preserved
tubules and minimally sclerosed glomeruli in a biopsy
performed before revascularization. Groups skilled in re-
vascularization surgery reported improvement or stabi-
lization of renal function in 79% to 90% of cases and a
progressive decline in 10% to 20% of cases. Surgery-
related mortality was 4.6% and was associated with the
elderly and with symptoms of congestive heart failure
[28].
CONCLUSION
IN is a pathology that is increasing in prevalence and
for which early diagnosis is essential to avoid progression
to irreversible renal insufficiency. Once the diagnosis has
been confirmed, it is essential to evaluate the advantages
and risks of potential renal revascularization techniques
on an individual basis.
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